Lung Cancer
Conference Coverage
‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
News
Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC
The disease control rate was 90%, the median progression-free survival was 9.3 months, and few patients required treatment modifications.
News
FDA expands approval of atezolizumab in NSCLC
–s...
News
FDA approves chemo-free combo for lung cancer
News
COVID-19 death rate was twice as high in cancer patients in NYC study
The overall case fatality rate was 28% for cancer patients with COVID-19 and 14% for noncancer COVID-19 patients.
News
Three months of COVID-19 may mean 80,000 missed cancer diagnoses
A backlog of 22 million canceled or postponed tests for five common cancers is expected by early June.
News
Cancer screening, monitoring down during pandemic
Use of some tests came to “a near standstill” in early April.
News
Excess cancer deaths predicted as care is disrupted by COVID-19
Conference Coverage
Antitumor treatment may increase risk of severe events in COVID-19 patients